MedX(R) Receives FDA Clearance for Oralase(TM), an Advanced Laser Treatment for Pain

    Technology4Medicine to have exclusive U.S. distribution rights for
    Oralase in the U.S.

    MISSISSAUGA, ON, Oct. 6 /CNW/ - MedX Health Corp. (TSXV: MDX), a global
leader in developing drug free, non-invasive therapeutics for tissue repair
and pain relief, today announced that the Oralase(TM) Portable Laser has been
cleared for marketing by the Food and Drug Administration (FDA). MedX's
distribution partner, Technology4Medicine, a laser company in San Clemente, CA
will begin immediate distribution of Oralase to dental offices in the United
States. Oralase is a photobiomodulation device, also known as low level laser
therapy (LLLT), exclusively designed for dentists to alleviate pain and
accelerate tissue repair following dental procedures.
    "We are very pleased to have received the 510(k) Clearance Letter from
the FDA so that we can begin to immediately provide the dental community with
our non-invasive and drug free solution to relieve pain due to surgical and
other procedures. Oralase will not only relieve the pain by accelerating
tissue repair, but it will provide patients the increased comfort of
accelerated healing," said Steve Guillen B.Sc., M.B.A., president and chief
executive officer, MedX Health. "Through our partnership with
Technology4Medicine, we expect to fulfill a great unmet need in the dental
community as well as other markets including dermatology and plastic surgery."
    "With this FDA clearance, we will offer Oralase to dentists across the
U.S. taking dentistry to a new level, increasing production for the dental
office, and providing a better experience for patients," stated Jeffrey W.
Jones, chief executive officer of Technology4Medicine. "We are looking forward
to launching Oralase at booth No.3051 at the upcoming American Dental
Association meeting in San Antonio, TX, October 15-18. Oralase should be a
fundamental component of today's high tech practice. It can dramatically
differentiate today's dentist. We believe we have a winning formula in
bringing the latest technology for quick uptake and use in this $1 Billion

    About Oralase(TM)
    Oralase is an ergonomically designed portable low level laser device that
offers dental staff a proven, drug-free solution to reduce or eliminate pain
and accelerate soft and hard tissue repair. Oralase is designed to effectively
control pain and decrease swelling from invasive dental procedures as well as
stimulate healing.

    About Low-Level Laser Therapy
    For more than 35 years, LLLT has been used in Europe, Australia, Asia and
Russia for the treatment of pain and tissue repair. MedX's LLLT was approved
in Canada in 1999 and in the United States in 2002. LLLT uses a specific type
of light to penetrate the skin's surface and underlying tissues to stimulate
the body's natural repair processes. The result is faster healing and reduced
pain, swelling and inflammation. The technology has advanced laser therapy
significantly, and Oralase embodies the new generation of photobiomodulation
technology for health care today.

    About MedX Health Corp.
    MedX is a leading North American developer and manufacturer of low level
laser and light medical devices, including dental, rehabilitation and wound
care products. MedX is the world's only company focusing on developing and
delivering a broad cross-section of technologies and products involved in
healing using light therapy. MedX is committed to advocating for and bringing
the non-invasive, drug-free healing nature of light to people seeking relief
from pain and other physical ailments.
    MedX plans to use the proceeds from its recent public offering to expand
its distribution network; support its marketing program; continue development
of new dental, rehabilitation and wound care products; undertake research and
development for wound care products; and for working capital purposes. In
particular, MedX plans to accelerate the development of a new product aimed at
the rapidly-growing wound care market: its "Photobandage", a bandage
technology that allows a wound to be bathed in light, designed to enhance the
healing process. The Company intends to license this new technology to one or
more major wound care companies for further development, marketing and sales.
For more information, visit

    About Technology4Medicine, LLC
    Technology4Medicine and its Technology4Therapy division are committed to
providing effective advanced technology to doctors and patients improving
clinical outcomes, enhancing the quality of care, enhancing the patient
experience and the clinician's return on investment. Technology4Medicine is
focused on ensuring customers have state-of-the-art technology and the highest
quality of customer support, technical service and clinical training in the
industry. For more information, visit

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this press release.

    This press release contains "forward-looking information" within the
meaning of applicable Canadian securities legislation. Such forward-looking
information may include statements regarding the Company's future plans,
objectives, performance, growth, profits, operating expenses or its underlying
assumptions. Generally, forward-looking information can be identified by the
use of forward-looking terminology such as "plans", "expects", or "does not
expect", "is expected", "budget", "scheduled", "estimates", "forecasts",
"intends", "anticipates", or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might", or "will be taken", "occur", or "be
achieved". Forward-looking information is subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of MedX to be materially different from
those expressed or implied by such forward-looking information, including
uncertainty of successful development of new products, uncertainty of
successful manufacturing or marketing of products, uncertainty of commercial
acceptance of products, uncertainty concerning governmental regulation,
dependency on key employees and relationships, rapid technological changes,
foreign currency fluctuations. MedX does not undertake to update any
forward-looking information, except in accordance with applicable securities

    %SEDAR: 00017466E

For further information:

For further information: Investors: Steve Guillen, President & CEO, MedX
Health Corp., Phone: (905) 826-0766, Email:; Media:
Terri Clevenger, Continuum Health Communications, Phone (203) 227-0209, Email:; Technology4Medicine contact: Jeff Jones,
Chief Executive Officer, Technology4Medicine, Phone: (949) 361-1682, Email:

Organization Profile

MedX Health Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890